tradingkey.logo
搜索

NewcelX Ord Shs

NCEL
添加自选
2.610USD
-0.080-2.97%
收盘 11-13 16:00(美东)
14.04M总市值
0.00市盈率 TTM

关于 NewcelX Ord Shs 公司

NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.

NewcelX Ord Shs 简介

公司代码- -
公司名称- -
上市日期- -
CEO- -
员工数量- -
证券类型- -
年结日- -
公司地址- -
城市- -
上市交易所- -
国家- -
邮编- -
电话- -
网址- -
公司代码- -
上市日期- -
CEO- -

NewcelX Ord Shs公司高管

名称
名称/职务
职务
持股
持股变动
Prof. Michel Revel, M.D., Ph.D.
Prof. Michel Revel, M.D., Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
976.43K
+5.59%
Prof. Michel Revel, M.D., Ph.D.
Prof. Michel Revel, M.D., Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
976.43K
+5.59%
Prof. Michel Revel, M.D., Ph.D.
Prof. Michel Revel, M.D., Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
976.43K
+5.59%
Mr. Ronald Hafner
Mr. Ronald Hafner
Independent Chairman of the Board
Independent Chairman of the Board
438.17K
+29.59%
Mr. Ronen Twito, CPA
Mr. Ronen Twito, CPA
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
272.40K
+9.50%
Mr. Ronen Twito, CPA
Mr. Ronen Twito, CPA
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
272.40K
+9.50%
Mr. Ronen Twito, CPA
Mr. Ronen Twito, CPA
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
272.40K
+9.50%
Mr. Olivier Samuel
Mr. Olivier Samuel
Non-Executive Independent Director
Non-Executive Independent Director
81.82K
--
Mr. Olivier Samuel
Mr. Olivier Samuel
Non-Executive Independent Director
Non-Executive Independent Director
81.82K
--
Mr. Olivier Samuel
Mr. Olivier Samuel
Non-Executive Independent Director
Non-Executive Independent Director
81.82K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Prof. Michel Revel, M.D., Ph.D.
Prof. Michel Revel, M.D., Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
976.43K
+5.59%
Prof. Michel Revel, M.D., Ph.D.
Prof. Michel Revel, M.D., Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
976.43K
+5.59%
Prof. Michel Revel, M.D., Ph.D.
Prof. Michel Revel, M.D., Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
976.43K
+5.59%
Mr. Ronald Hafner
Mr. Ronald Hafner
Independent Chairman of the Board
Independent Chairman of the Board
438.17K
+29.59%
Mr. Ronen Twito, CPA
Mr. Ronen Twito, CPA
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
272.40K
+9.50%
Mr. Ronen Twito, CPA
Mr. Ronen Twito, CPA
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
272.40K
+9.50%

常见问题

NewcelX Ord Shs的前五大股东是谁?

NewcelX Ord Shs 的前五大股东如下:Prof. Michel Revel, M.D., Ph.D.
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有